Elevation Oncology — Corporate Update (July 2022)
16 slides from Elevation Oncology's corporate update, Jul 28, 2022
Slide 1: Expanding Pipeline with EO-3021 Investor Conference Call
Expanding Pipeline with EO - 3021 Investor Conference Call JULY 28, 2022
Slide 2: Forward Looking Statements
Forward Looking Statements These slides contain forward - looking statements and information relating to Elevation Oncology, Inc. within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on f
Slide 3: Today's Agenda
Overview of the Deal Role of Claudin18.2 in Cancer Opportunity for EO - 3021 Closing Remarks 3 Today’s Agenda Shawn M. Leland, PharmD RPh FOUNDER AND CHIEF EXECUTIVE OFFICER David Dornan, PhD CHIEF SCIENTIFIC OFFICER Valerie M. Jansen, MD PhD CHIEF MEDICAL OFFICER Shawn M. Leland, PharmD RPh FOUNDER
Slide 4: Overview of the Deal
4 Shawn M. Leland , PharmD RPh OVERVIEW OF THE DEAL FOUNDER AND CHIEF EXECUTIVE OFFICER
Slide 5: Building a Leading Precision Oncology Pipeline
5 Building a Leading Precision Oncology Pipeline Strategy for Pipeline Expansion 1 The CRESTONE study is designed as a potential registrational trial following an accelerated approval pathway contingent upon con tinued discussions with the FDA 2 Report additional clinical data from Cohort 1 of the C
Slide 6: Expanding Pipeline with a Differentiated ADC Candidate Targeting Claudin18.2
6 EO - 3021 Expanding Pipeline with a Differentiated ADC Candidate Targeting an Attractive Market Opportunity in Claudin18.2 Claudin18.2 expressed across several solid tumor types including many GI cancers Clinically validated oncology target Potential for EO - 3021 to play a transformative role in
Slide 7: Role of Claudin18.2 in Cancer
7 David Dornan, PhD ROLE OF CLAUDIN18.2 IN CANCER CHIEF SCIENTIFIC OFFICER
Slide 8: Claudin18.2 is a Unique and Highly Selective Target
Claudin18.2 is a Unique and Highly Selective Target 8 ● Claudin18.2 is a highly selective cell surface target often overexpressed in several types of cancers ● Claudin18.2 is largely inaccessible to antibodies in normal tissue, but is exposed on epithelial surface during tumorigenesis ● Overexpresse
Slide 9: A Differentiated ADC Targeting Claudin18.2
EO - 3021 – A Differentiated ADC Targeting Claudin18.2 9 Linker Anti - Claudin18.2 Antibody MMAE Payload
Slide 10: Opportunity for EO-3021
10 Valerie M. Jansen, MD PhD OPPORTUNITY FOR EO - 3021 CHIEF MEDICAL OFFICER
Slide 11: Significant Global Opportunity for Patients with Tumors Expressing Claudin18.2
● O verexpressed in several high unmet need cancers, including gastric, esophageal, pancreatic, ovarian, and NSCLC, among others ● Expression is highest in GC/GEJ and pancreatic tumors (≥70%) ● Elevation Oncology’s license to EO - 3021 is for all global territories outside Greater China Significant
Slide 12: Expected to Enter US Clinical Trials in 2023
12 EO - 3021 Expected to Enter US Clinical Trials in 2023 Ongoing Phase 1 dose - escalation and dose - expansion study of EO - 3021 (SYSA1801) being conducted in China by CSPC IND cleared for EO - 3021 in US US Phase 1 clinical trial of EO - 3021 expected to be initiated by Elevation Oncology in 202
Slide 13: Closing Remarks
13 Shawn M. Leland , PharmD RPh CLOSING REMARKS FOUNDER AND CHIEF EXECUTIVE OFFICER
Slide 14: Building an Industry-Leading Precision Oncology Company
14 Obtained exclusive worldwide rights (outside Greater China) to develop and commercialize EO - 3021 EO - 3021 is a potential first - in - class, best - in - class, clinical - stage ADC targeting Claudin18.2 and currently in Phase 1 dose - escalation trial in China Claudin18.2 is clinically validat
Slide 15: Key Upcoming Milestones
15 KEY UPCOMING MILESTONES *As of March 31, 2022 ~$132.1M cash and cash equivalents* Cash runway into 2024 Mid - 2022 Report initial data from CRESTONE Cohort 1 SERIBANTUMAB First Half 2023 Report additional interim data from CRESTONE Cohort 1 Mid - 2022 Complete enrollment of the first 20 patients
Slide 16: Q&A
Q&A Shawn M. Leland, PharmD RPh Founder and CEO David Dornan, PhD Chief Scientific Officer Valerie M. Jansen, MD PhD Chief Medical Officer Joseph Ferra Chief Financial Officer